IL270801A - NKG2D, CD16 and tumor-associated antigen binding protein - Google Patents

NKG2D, CD16 and tumor-associated antigen binding protein

Info

Publication number
IL270801A
IL270801A IL270801A IL27080119A IL270801A IL 270801 A IL270801 A IL 270801A IL 270801 A IL270801 A IL 270801A IL 27080119 A IL27080119 A IL 27080119A IL 270801 A IL270801 A IL 270801A
Authority
IL
Israel
Prior art keywords
tumor
protein binding
associated antigen
binding nkg2d
nkg2d
Prior art date
Application number
IL270801A
Other languages
English (en)
Hebrew (he)
Inventor
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Bianka Prinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc, Gregory P Chang, Ann F Cheung, William Haney, Bradley M Lunde, Bianka Prinz filed Critical Dragonfly Therapeutics Inc
Publication of IL270801A publication Critical patent/IL270801A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL270801A 2017-05-23 2019-11-20 NKG2D, CD16 and tumor-associated antigen binding protein IL270801A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762510168P 2017-05-23 2017-05-23
US201762510167P 2017-05-23 2017-05-23
US201762510169P 2017-05-23 2017-05-23
US201762510137P 2017-05-23 2017-05-23
US201762539425P 2017-07-31 2017-07-31
PCT/US2018/034221 WO2018217945A1 (en) 2017-05-23 2018-05-23 A protein binding nkg2d, cd16 and a tumor-associated antigen

Publications (1)

Publication Number Publication Date
IL270801A true IL270801A (en) 2020-01-30

Family

ID=64395873

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270801A IL270801A (en) 2017-05-23 2019-11-20 NKG2D, CD16 and tumor-associated antigen binding protein

Country Status (11)

Country Link
US (1) US20200157226A1 (enExample)
EP (1) EP3630181A4 (enExample)
JP (2) JP2020522474A (enExample)
KR (1) KR20200010429A (enExample)
CN (1) CN111278460A (enExample)
AU (1) AU2018273250A1 (enExample)
BR (1) BR112019024620A2 (enExample)
CA (1) CA3064567A1 (enExample)
IL (1) IL270801A (enExample)
MX (1) MX2019013995A (enExample)
WO (1) WO2018217945A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US20230287081A1 (en) * 2020-04-16 2023-09-14 Nantong Yichen Biopharma. Co. Ltd. PD-1 mutant polypeptide and preparation and application thereof
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CA3233377A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and baff-r
US20230203202A1 (en) * 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
AU2023382738A1 (en) 2022-11-15 2025-05-29 Abbvie Inc. Anti-papp-a antibodies and methods of use thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5972915B2 (ja) * 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
PT2900694T (pt) * 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
TN2016000525A1 (en) * 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US10941207B2 (en) * 2014-12-19 2021-03-09 Chiome Bioscience, Inc Fusion protein comprising three binding domains to 5T4 and CD3
TW201627322A (zh) * 2015-01-26 2016-08-01 宏觀基因股份有限公司 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
US10973914B2 (en) * 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
EP3374389A1 (en) * 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
US20200048347A1 (en) * 2016-09-01 2020-02-13 Immunomab, Inc. Bispecific antibodies
IL268554B2 (en) * 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer

Also Published As

Publication number Publication date
JP2020522474A (ja) 2020-07-30
CN111278460A (zh) 2020-06-12
EP3630181A4 (en) 2021-03-17
US20200157226A1 (en) 2020-05-21
RU2019142714A3 (enExample) 2021-10-22
JP2023030174A (ja) 2023-03-07
AU2018273250A1 (en) 2019-12-12
WO2018217945A1 (en) 2018-11-29
EP3630181A1 (en) 2020-04-08
CA3064567A1 (en) 2018-11-29
RU2019142714A (ru) 2021-06-23
KR20200010429A (ko) 2020-01-30
BR112019024620A2 (pt) 2020-06-23
MX2019013995A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
IL281323A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL270801A (en) NKG2D, CD16 and tumor-associated antigen binding protein
SG11202101294RA (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL268755B2 (en) Proteins that bind her2, nkg2d, and cd16
SG11202101298XA (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL270794A (en) NKG2D binding protein, CD16 and ROR1 or ROR2
IL268790A (en) CD33, NKG2D and CD16 binding proteins
IL280656A (en) Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use
IL268567A (en) BCMA, NKG2D and CD16 binding proteins
IL268574A (en) proteins that bind psma, nkg2d, and cd16
IL268766A (en) Proteins that bind NKG2D, CD123, and CD16
SG11202000632QA (en) Proteins binding nkg2d, cd16 and flt3
IL268768A (en) Proteins binding gd2, nkg2d and cd16
SG11202011139YA (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
IL275391A (en) CTLA-4 binding antibodies and their uses
HK40027627A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
HK40027626A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
HK40054606A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
ZA201905273B (en) Proteins binding psma, nkg2d and cd16
HK40019734A (en) Proteins binding cd123, nkg2d and cd16
HK40019178A (en) Proteins binding psma, nkg2d and cd16
HK40030226A (en) Proteins binding nkg2d, cd16 and flt3
HK40027628A (en) A protein binding nkg2d, cd16 and ror1 or ror2